EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Tuesday, October 22nd 2019 at 12:00pm UTC CARLSBAD, Calif.–(BUSINESS WIRE)– Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brandi L. Roberts, Chief Financial Officer, will be presenting at the Dawson James Securities 5th Annual …
Plus »Quotient Sciences Appoints Claes Glassell as Non-Executive Chairman of Board of Directors
Tuesday, October 22nd 2019 at 1:00pm UTC NOTTINGHAM, England–(BUSINESS WIRE)– Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non-executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held …
Plus »Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF Mutation
Monday, October 21st 2019 at 10:01pm UTC BETHESDA, Md.–(BUSINESS WIRE)– Today’s FDA approval of TRIKAFTA (elexacaftor/ivacaftor/tezacaftor), the highly effective and highly anticipated triple-combination CFTR modulator, marks the start of a new era in cystic fibrosis. This medicine represents the single greatest therapeutic advancement in the history of CF, offering a …
Plus »Retrospective Real-World Comparative Analysis Highlights Safety of Vedolizumab and Anti-TNF? Therapies in Biologic-Naïve Patients with Ulcerative Colitis or Crohn’s Disease
Monday, October 21st 2019 at 5:00am UTC – Latest real-world data presented at UEG Week 2019 complements the extensive body of clinical evidence for the gut-selective biologic vedolizumab in biologic-naïve patients with moderately to severely active ulcerative colitis or Crohn’s disease OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) …
Plus »Takeda obtient une licence pour le traitement de la maladie cœliaque de première classe de COUR Pharmaceuticals à la suite d’une étude de validation de principe positive de phase 2a
Tuesday, October 22nd 2019 at 6:15pm UTC ? Les données les plus récentes d’une étude de phase 2a présentée lors de la UEG Week 2019, à Barcelone, en Espagne, soulignent le potentiel de la médecine expérimentale pour prévenir l’activation immunitaire induite par le gluten chez les patients atteints de la …
Plus »STALICLA nomme Stéphane Baudouin au poste de responsable scientifique
Tuesday, October 22nd 2019 at 7:34pm UTC Le neurobiologiste met ses 10 années d’expérience dans les Troubles du Spectre Autistique au service de la stratégie de recherche de la startup Biotech Suisse GENÈVE–(BUSINESS WIRE)– STALICLA est ravie d’annoncer la nomination de Stéphane Baudouin au poste de responsable scientifique à compter …
Plus »Global Cell Harvesting Markets Through 2019-2025 | Anticipating a CAGR of 8.4% During the Forecast Period – ResearchAndMarkets.com
Tuesday, October 22nd 2019 at 5:04pm UTC DUBLIN–(BUSINESS WIRE)– The « Cell Harvesting – Market Analysis, Trends, and Forecasts » report has been added to ResearchAndMarkets.com’s offering. The Cell Harvesting market worldwide is projected to grow by US$157.2 Million, driven by a compounded growth of 8.4%. Manual Cell Harvesters, one of the …
Plus »Systems Oncology Receives Investment from The Pritzker Organization
Tuesday, October 22nd 2019 at 1:00pm UTC SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Systems Oncology, LLC (“SO”) and The Pritzker Organization, LLC (“TPO”) announced today that Pritzker Family Business Interests advised by TPO have invested in the first closing of SO’s Series B round. The funding will be used to invest in both …
Plus »Tiaki Therapeutics Presents Data on Identification of a Novel Target for Neuroinflammatory-driven Neurodegenerative Disease Validated by Its Systems Biology Platform
Monday, October 21st 2019 at 4:00pm UTC Proprietary platform recapitulates neuroinflammatory signature from Alzheimer’s Disease patients Data presented at Society for Neuroscience 49th Annual Meeting CAMBRIDGE, Mass.–(BUSINESS WIRE)– Tiaki Therapeutics, a company developing treatments for patients suffering from age-related dementias by targeting the neuroinflammation that drives cognitive decline, announced today …
Plus »SkyKnight Capital Invests in Home Healthcare Leader AeroCare
Monday, October 21st 2019 at 12:00pm UTC SAN FRANCISCO–(BUSINESS WIRE)– SkyKnight Capital (“SkyKnight”), a San Francisco based private equity firm, announced that it has made an investment into AeroCare Holdings, Inc. (“AeroCare” or the “Company”), a leading provider of home healthcare solutions focused on patients with chronic respiratory conditions. AeroCare …
Plus »
